On Friday, the U.S. District Court for the District of Columbia granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking Edwards Lifesciences Corp’s (NYSE:EW) proposed acquisition of JenaValve Technology Inc.

As a result, Edwards will not acquire JenaValve.

Edwards said it disagrees with the decision and believes that the acquisition would have been in the best interest of a large, growing, and underserved group of patients.

Aortic regurgitation (AR) is a heart condition where the aortic valve doesn’t close tightly, causing blood to leak backward from the aorta into the left ventricle, making the heart work harder.

The company on Friday said AR is typically under-detected and under-referred, and carries very high mortality if left untreated.

Edwards said it is advancing ...